Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?

Eur Heart J. 2019 May 7;40(18):1466-1471. doi: 10.1093/eurheartj/ehy347.

Authors

K A A Fox¹, J W Eikelboom², S S Anand², D L Bhatt³, J Bosch², S J Connolly², R A Harrington⁴, P G Steg⁵, S Yusuf²

Affiliations

¹ Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, UK.
² Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON, Canada.
³ Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, USA.
⁴ Stanford University, 300 Pasteur Dr, Stanford, CA, USA.
⁵ Assistance Publique-Hôpitaux de Paris, 3 Avenue Victoria, Paris, France.

PMID: 29945212
DOI: 10.1093/eurheartj/ehy347

No abstract available

Publication types

Comparative Study

MeSH terms

Aspirin / adverse effects
Aspirin / therapeutic use
Atherosclerosis / complications*
Chronic Disease
Clinical Trials as Topic
Death
Drug Therapy, Combination
Factor Xa Inhibitors / adverse effects
Factor Xa Inhibitors / therapeutic use
Fibrinolytic Agents / adverse effects*
Fibrinolytic Agents / therapeutic use
Hemorrhage / chemically induced
Hemorrhage / epidemiology
Humans
Myocardial Infarction / epidemiology
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use
Rivaroxaban / adverse effects
Rivaroxaban / therapeutic use
Secondary Prevention / methods*
Stroke / epidemiology
Thrombosis / prevention & control
Vascular Diseases / pathology*
Vascular Diseases / prevention & control

Substances

Factor Xa Inhibitors
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Rivaroxaban
Aspirin